These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 35748082)
1. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa. Kwak JJ; Kim HR; Byeon SH Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082 [TBL] [Abstract][Full Text] [Related]
2. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis. Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313 [TBL] [Abstract][Full Text] [Related]
3. The first gene therapy for Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119 [TBL] [Abstract][Full Text] [Related]
7. Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy. Yang U; Gentleman S; Gai X; Gorin MB; Borchert MS; Lee TC; Villanueva A; Koenekoop R; Maguire AM; Bennett J; Redmond TM; Nagiel A JAMA Ophthalmol; 2019 Dec; 137(12):1381-1388. PubMed ID: 31580392 [TBL] [Abstract][Full Text] [Related]
8. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network. Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN; Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911 [TBL] [Abstract][Full Text] [Related]
9. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec. Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237 [TBL] [Abstract][Full Text] [Related]
10. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis. Hussain RM; Tran KD; Maguire AM; Berrocal AM Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202 [TBL] [Abstract][Full Text] [Related]
11. Properties and Therapeutic Implications of an Enigmatic D477G RPE65 Variant Associated with Autosomal Dominant Retinitis Pigmentosa. Kiang AS; Kenna PF; Humphries MM; Ozaki E; Koenekoop RK; Campbell M; Farrar GJ; Humphries P Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33261050 [TBL] [Abstract][Full Text] [Related]
12. Surgical Observations From the First 120 Cases of Subretinal Gene Therapy for Inherited Retinal Diseases. Gregori NZ; Davis JL Retina; 2023 Sep; 43(9):1608-1611. PubMed ID: 33394965 [TBL] [Abstract][Full Text] [Related]
13. Voretigene neparvovec-rzyl for treatment of Ciulla TA; Hussain RM; Berrocal AM; Nagiel A Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547 [No Abstract] [Full Text] [Related]
14. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence. Kolesnikova M; Lima de Carvalho JR; Parmann R; Kim AH; Mahajan VB; Tsang SH; Sparrow JR Mol Genet Genomic Med; 2022 Nov; 10(11):e2038. PubMed ID: 36225124 [TBL] [Abstract][Full Text] [Related]
15. [Gene therapy for vision restoration in patients with Leber congenital amaurosis (LCA) due to RPE65 gene mutations: beginning the phase IV trial]. Chacón-Camacho ÓF; Zenteno JC Gac Med Mex; 2017; 153(2):276-278. PubMed ID: 28474714 [TBL] [Abstract][Full Text] [Related]
16. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia]. Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591 [TBL] [Abstract][Full Text] [Related]
17. Visual acuity in patients with Leber's congenital amaurosis and early childhood-onset retinitis pigmentosa. Walia S; Fishman GA; Jacobson SG; Aleman TS; Koenekoop RK; Traboulsi EI; Weleber RG; Pennesi ME; Heon E; Drack A; Lam BL; Allikmets R; Stone EM Ophthalmology; 2010 Jun; 117(6):1190-8. PubMed ID: 20079931 [TBL] [Abstract][Full Text] [Related]
18. Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Testa F; Bacci G; Falsini B; Iarossi G; Melillo P; Mucciolo DP; Murro V; Salvetti AP; Sodi A; Staurenghi G; Simonelli F Eye (Lond); 2024 Sep; 38(13):2504-2515. PubMed ID: 38627549 [TBL] [Abstract][Full Text] [Related]
19. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650 [TBL] [Abstract][Full Text] [Related]
20. Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations. Roman AJ; Cideciyan AV; Schwartz SB; Olivares MB; Heon E; Jacobson SG Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1378-83. PubMed ID: 23341016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]